

# Fenton-Hydroxyl Radical Antioxidant Efficiency of Ibuprofen- $\text{Fe}_3\text{O}_4$ -GO Nanospheres

Aleksey Drinevskiy, Evgenij Zelkovskiy, Vladimir Labunov, and Darya Radziuk\*



Cite This: <https://doi.org/10.1021/acsnm.3c05399>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

**ABSTRACT:** A feasible one-step “solvent-antisolvent” oil-free acoustic emulsification method is demonstrated for the complexation of pristine ibuprofen with  $\text{Fe}_3\text{O}_4$ -GO in the form of nanospheres with a core-shell structure ( $\sim 50$  nm). The ultrasonic complexation occurs via the H-bond formation with the ibuprofen side chains ( $\text{CH}$ ,  $\text{CH}_2$ , and  $\text{CH}_3$ ) and  $\text{C}-\text{O}-\text{H}$  involving the interaction of carboxylic groups and  $\text{Fe}-\text{O}$  bonds. Synthesized ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres are efficient antioxidants with hydroxyl radical ( $\cdot\text{OH}$ ) scavenging and iron inactivation properties in the electro-Fenton process exhibiting  $\sim 24$  times higher diminishing rate than free ibuprofen per se and  $\sim 161$  times higher than pristine ibuprofen nanoparticles in aqueous medium. This pronounced antioxidant efficiency of ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres is due to the increased concentration of inactive protonated  $\text{Fe}(\text{II})$  centers in  $\text{Fe}-\text{O}$ ,  $\text{C}-\text{Fe}$ , and  $\text{CO}-\text{Fe}$  bonds ( $\text{FeO}^+$ ,  $\text{CFe}^+$ , and  $\text{COFe}^+$ ) of complexed drug molecules and increased concentration of  $\text{CHO}_2^+$ ,  $\text{OH}^+$ , and  $\text{CO}^+$  ions on the surface of nanospheres. The demonstrated method discloses the conditions of enhanced antioxidant efficiency of ibuprofen and defines the roles of  $\text{Fe}_3\text{O}_4$  and GO in two basic fundamental COX-independent mechanisms.

**KEYWORDS:** graphene oxide, NSAID, iron oxide, ultrasound, metallodrug, Fenton, catalyst



## 1. INTRODUCTION

Ibuprofen is one of the most useful nonsteroidal anti-inflammatory drugs (NSAIDs) available to humans to treat oxidant-mediated inflammatory diseases such as arthritis and musculoskeletal and rheumatic disorders.<sup>1</sup> Treatment of these diseases requires efficient molecules to attenuate reactive oxygen species (ROS) generation. The process of ROS formation is complex in cellular metabolic homeostasis and involves two defined mechanisms based on conversion of oxygen and hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) through the generation of ferrous ion  $\text{Fe}(\text{II})$ , impelling hydroxyl ( $\cdot\text{OH}$ ) radical production via Fenton reactions.<sup>2</sup>  $\cdot\text{OH}$  radicals can be also produced via Haber-Weiss reactions involving  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$ .<sup>3</sup> Among ROS species,  $\cdot\text{OH}$  radicals are most destructive to cells because they cause the breakage of DNA strands, damage proteins, and lipids via peroxidation, induce mutagenesis or inhibit cancer suppressors.<sup>4</sup> As a result, intracellular free iron ions and highly reactive radical species can interact via the Fenton reaction, and interfere with the cell signaling processes, immunoregulation, and inflammation via induction of cytotoxicity.

Inhibition of intracellular ROS production such as  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$  by ibuprofen has been reported.<sup>5</sup> Ibuprofen can scavenge the generated free oxygen radicals through the modification of low-density lipoproteins.<sup>6,7</sup> The ability of ibuprofen to suppress iron-mediated hydroxyl radical ( $\cdot\text{OH}$ ) generation from hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) was revealed in the Fenton reaction too.<sup>8</sup> Scavenging of  $\cdot\text{OH}$  radicals, i.e., free radical inactivation, may be one of the antioxidant mechanisms of

ibuprofen in the treatment of rheumatic diseases.<sup>9</sup> In this way, 46 in the electro-Fenton process ibuprofen exhibits a dual action: 47 one that is related to the iron chelation, and the other one that 48 involves the scavenging of  $\cdot\text{OH}$  radicals, leading to the 49 production of reactive ibuprofen radicals that may be 50 associated with the reported cytotoxicity of this drug.<sup>10</sup> 51 Thus, ibuprofen can also act as a prooxidant as it is able to 52 reduce  $\text{Fe}(\text{III})$ .<sup>11</sup> Therefore, the free radical inactivation by 53 ibuprofen may be related either to hydrogen atom transfer via 54 inactivation of free radicals through H donation or single 55 electron transfer. 56

The antioxidant action of pristine ibuprofen was confirmed 57 in the prevention of lung injury caused by oxidation and lipid 58 peroxidation via chelation of iron, resulting in the formation of 59 iron chelates that lack the free coordination site required for 60 iron.<sup>12</sup> The antioxidant efficiency of ibuprofen is drug 61 concentration-dependent: at a low concentration relative to 62 that of iron, the drug acts as an efficient  $\cdot\text{OH}$  radical scavenger; 63 at a higher concentration, excess of drug molecules inhibit the 64 Fenton reaction and prevent  $\text{H}_2\text{O}_2$  consumption by rendering 65 iron nonreactive. Results show that the propionic acid group of 66 ibuprofen can chelate iron, whereas its isobutylbenzene 67

**Received:** November 11, 2023

**Revised:** January 4, 2024

**Accepted:** January 5, 2024

68 molecular part can contribute to the scavenging of  $\cdot\text{OH}$   
69 radicals. Therefore, iron chelation may play a central role in  
70 ibuprofen's antioxidant mechanism of action and increase its  
71 biological function in analogy with the chelation activity of  
72 metals by organic substances, leading to selective cytotoxicity  
73 effects.<sup>13</sup>

74 The role of carboxylic groups in iron chelation by ibuprofen  
75 is crucial as it was evidenced that if the carboxylic acid group of  
76 ibuprofen was replaced by an ester, alcohol, amide, or tetrazole  
77 the anti-inflammatory activity of this drug was significantly  
78 reduced. Moreover, studies revealed that the antioxidant and  
79 antiradical activity of phenolic acids can be tightly linked to the  
80 number and position of  $-\text{OH}$  groups present on the aromatic  
81 ring. Therefore, the modification of pristine ibuprofen via  
82 metal complexation with its carboxylic group and aromatic C–  
83 C rings with its phenyl group could be a strategy to improve its  
84 antioxidant efficiency.

85 Modification of NSAIDs has been performed via metal ion  
86 complexation, e.g., mefenamic acid with Mn, Fe, Co, Ni, Cu, or  
87 Zn; diclofenac with Mn; indomethacin with Cu;<sup>14</sup> iron-  
88 salicylate complex<sup>15</sup> to produce antioxidant metallodrugs with  
89 ameliorated efficiency at the cellular level in comparison with  
90 pristine NSAIDs.<sup>16</sup> Previously, we have shown that complex-  
91 ation of pristine salicylic acid with  $\text{Fe}_3\text{O}_4$ -graphene oxide (GO)  
92 results in the formation of nanoparticles with intracellular  
93 switchable antioxidant function.<sup>17</sup> Magnetite nanoparticles  
94 (NPs) are biocompatible and exhibit negligible cytotoxicity,  
95 while GO provides a large surface active area, versatile  
96 chemistry, and enhanced stability of complexed molecules.  
97  $\text{Fe}_3\text{O}_4$ -GO nanoplateform is regarded as a promising contrast  
98 agent for magnetic resonance imaging (MRI) and can  
99 significantly increase the loading capacity of organic molecules  
100 due to the  $\pi$ – $\pi$  stacking and hydrogen bonding.<sup>18</sup> From a  
101 biological point of view,  $\text{Fe}_3\text{O}_4$ -GO can increase ROS  
102 production,  $\text{Ca}^+$  ion concentration, oxidative stress in  
103 mitochondria and activate Caspase-9 and Caspase-3 leading  
104 to cell apoptosis.<sup>19</sup> As  $\text{Fe}_3\text{O}_4$ -GO exhibits peroxidase-like  
105 activity, it can be potentially applied as a nanozyme.<sup>20</sup> At  
106 present  $\text{Fe}_3\text{O}_4$ -GO has been produced for loading with various  
107 drugs such as doxorubicin,<sup>21</sup> 5-fluorouracil,<sup>22</sup> camptothecin  
108 and methotrexate<sup>23</sup> and ultrasonic (20 kHz) functionalization  
109 of ketorolac<sup>24</sup> and acetylsalicylic acid (ASA).<sup>25</sup> Iron-based  
110 drugs are of special interest because Fe is a transition metal,  
111 which has multiple stable oxidation states and its redox  
112 chemistry can be accurately controlled.<sup>26</sup> However, only a few  
113 iron-based drugs (e.g., Proferdex, Dexterrum, InFeD, Venofer)  
114 are in clinical trials because the exact molecular mechanisms of  
115 their function and catalytic activity are not fully understood in  
116 the biological environment. Therefore, new methods of drug  
117 modification are needed to find conditions of metallodrug  
118 improved functionalization and efficiency.

119 Many methods have been introduced for metallodrug  
120 functionalization such as chemical metal-peptidic bioconjugation,<sup>27</sup>  
121 DNA G-quadruplex conjugation,<sup>28</sup> bioorthogonal  
122 synthetic lethality,<sup>29</sup> multiomics<sup>30</sup> and ultrasonic complexation  
123 via redox sonochemistry.<sup>31</sup> Sonochemistry can be related to  
124 one of the efficient tools to modify metallodrugs through the  
125 redox reactions of radical species, molecular assembly, and  
126 encapsulation mechanisms.<sup>32–35</sup> Up to now, sonochemistry  
127 has been applied to study sonofragmentation of pristine  
128 acetylsalicylic acid,<sup>36</sup> paracetamol, phenacetin, and sulfadime-  
129 thoxine.<sup>37</sup> Another direction was to use a sonochemical  
130 emulsification tool for encapsulation of bioactive materials

(paclitaxel, gemcitabine HCl, tetracycline, rifampicin, acetylsalicylic acid, a-tocopherol, piroxicam), RNA,  $\text{Fe}_3\text{O}_4$  NPs in nanoscale carriers composed of cross-linked proteinaceous shells.<sup>38</sup> So far sonochemistry has been applied to synthesize stable  $\text{Fe}_3\text{O}_4$  NPs,<sup>39</sup> to form  $\text{Fe}_3\text{O}_4$ -rGO<sup>40</sup> and graphene-dendrimeric  $\text{Fe}_3\text{O}_4$  NPs for loading with doxorubicin and melatonin;<sup>41</sup> to encapsulate  $\text{Fe}_3\text{O}_4$ -GO and doxorubicin with folic acid conjugated chitosan;<sup>42</sup> to prepare  $\text{Fe}_3\text{O}_4$ @PEI-rGO for extraction of polar NSAIDs;<sup>43</sup> to use  $\text{Fe}_3\text{O}_4$ -GO for adsorption of bisphenol A, naproxen, and triclosan;<sup>44</sup> to form  $\text{Fe}_3\text{O}_4$ @C-nanodot@GO for the magnetic solid phase extraction of ibuprofen in human blood;<sup>45</sup> to load  $\text{Fe}_3\text{O}_4$ -GO with rapamycin;<sup>46</sup> and to use poly(2-aminobenzothiazole)-coated  $\text{Fe}_3\text{O}_4$ -GO for adsorption and extraction of naproxen, diclofenac, and ibuprofen.<sup>47</sup> Nowadays, little is known about the functionalization of pristine ibuprofen by sonochemistry to form catalytic ibuprofen- $\text{Fe}_3\text{O}_4$ -GO with improved antioxidant function.

We introduce a feasible “solvent-antisolvent” oil-free acoustic emulsification method for the functionalization of pristine ibuprofen with  $\text{Fe}_3\text{O}_4$ -GO and determine the conditions of enhanced  $\cdot\text{OH}$  radical diminishing antioxidant activity of synthesized ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres. We show how this method enables efficient complexation of pristine ibuprofen with  $\text{Fe}_3\text{O}_4$  and GO and explain why it can be useful in the fundamental understanding of ibuprofen-Fe(II), ibuprofen–Fe–O, and ibuprofen–C–O–Fe bonding in the study of COX-independent mechanisms of NSAIDs, inactivation of metal ions, and scavenging of free radicals.

## 2. EXPERIMENTAL SECTION

**2.1. Materials and Synthesis.** Pyrolytic graphite (mechanically ground by 3 mm balls for 70 min and thermally treated at  $T = 100^\circ\text{C}$  for 240 min) with composition C ( $95.9 \pm 10.0$ ) at %, O ( $3.7 \pm 0.8$ ) at %, and impurities of Ca ( $0.3 \pm 0.1$ ) at % was used for the synthesis of GO (more details can be found in Supporting Information). Potassium permanganate ( $\text{KMnO}_4$ , 99%), sulfuric acid ( $\text{H}_2\text{SO}_4$ , 93 wt %), phosphoric acid ( $\text{H}_3\text{PO}_4$ , 87 wt %), hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 50 wt %), hydrogen chloride (HCl, 35 wt %), potassium hydroxide (KOH, 44 wt %), potassium chloride (KCl, 99.8%), sodium hydroxide (NaOH, 99%), disodium hydrogen phosphate ( $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 99%), citric acid (99%), isopropyl alcohol ( $\text{C}_3\text{H}_8\text{O}$ , 99.7%), ammonium hydroxide solution ( $\text{NH}_3 \cdot \text{H}_2\text{O}$ , 25 wt %), and ethanol ( $\text{C}_2\text{H}_5\text{OH}$ , 96.2%) are of higher grade purity being obtained from Belreachim JSC (Republic of Belarus). Iron(II) chloride ( $\text{FeCl}_2$ , 98%) and iron(III) chloride ( $\text{FeCl}_3$ , 97%) were purchased from Sigma-Aldrich GmbH. Ibuprofen per se (99.5%) was obtained from IOL Chemicals and Pharmaceuticals Ltd. (India).

**2.1.1. Synthesis of Ibuprofen- $\text{Fe}_3\text{O}_4$ -GO Nanospheres.** Ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres were synthesized by a “solvent-antisolvent” method with the use of an ultrasonic horn-type disperser with a diameter  $\sim 12 \times 10^{-3}$  m of the irradiating surface and a maximal vibration amplitude  $37 \times 10^{-6}$  m operating in a continuous mode at 20 kHz frequency with the 400 W maximal output power (Cavitation Inc., Belarus). The stock solutions of pristine ibuprofen at concentrations 5 mM and 25 mM in ethanol (81 wt %) were used as “solvent” fluids. The aqueous solutions of GO,  $\text{Fe}_3\text{O}_4$ , and  $\text{Fe}_3\text{O}_4$ -GO were applied as “antisolvent” fluids to prepare ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres, ibuprofen-GO, and ibuprofen- $\text{Fe}_3\text{O}_4$  colloids for comparison studies.

Before the synthesis, a stock solution of GO (1 mg/mL) was prepared in deionized (DI) water by sonication at the intensity of ultrasound  $24.54 \pm 0.01$  W/cm<sup>2</sup> for 165 min until the homogeneous suspension without a sediment was formed. A colloidal solution of  $\text{Fe}_3\text{O}_4$  was prepared in DI water by using a coprecipitation method, in which iron is precipitated from the mixture of  $\text{FeCl}_2$  and  $\text{FeCl}_3$  at a

195 molar ratio 1:2 in aqueous medium by addition of ammonium  
196 hydroxide solution in an argon atmosphere (more details in  
197 [Supporting Information](#)). The ultrasonic synthesis comprises the  
198 formation of Fe<sub>3</sub>O<sub>4</sub>-GO nanoplateform followed by its complexation  
199 with ibuprofen and ibuprofen-GO.

200 At first, preformed Fe<sub>3</sub>O<sub>4</sub> NPs in a powder form (1 mg/mL) were  
201 dispersed in 10 × 10<sup>-3</sup> L of an aqueous solution of GO (1 mg/mL)  
202 with ultrasound at intensity 16.36 ± 0.01 W/cm<sup>2</sup> for 60 min in an air  
203 atmosphere in an ice bath, resulting in the formation of Fe<sub>3</sub>O<sub>4</sub>-GO.  
204 Second, aqueous colloidal GO solution was dropwise added to 5 mM  
205 or 25 mM pristine ibuprofen solution (81 wt %) at the volume ratio  
206 1:1 during ultrasonic treatment under mechanical stirring and  
207 sonicated at the intensity of ultrasound 24.54 ± 0.01 W/cm<sup>2</sup> for 1  
208 min in an air atmosphere in the ice bath with the total volume of the  
209 reaction mixture 10 × 10<sup>-3</sup> L. Pristine ibuprofen or the half of the  
210 ibuprofen-GO suspension ("solvent") was used for complexation with  
211 Fe<sub>3</sub>O<sub>4</sub>-GO ("antisolvent").

212 In a reaction of complexation, the "solvent" was sonicated at 24.54  
213 ± 0.01 W/cm<sup>2</sup> while being dropwise added by an "antisolvent" at the  
214 volume ratio 1:1 and the reaction mixture was subjected to ultrasound  
215 for 3 min of total duration in an air atmosphere in ice bath to form  
216 ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres. Precipitation of obtained nano-  
217 particles was carried out by centrifugation of the colloidal suspension  
218 at a relative centrifugal force of 9.5 × g for 15 min in two cycles  
219 followed by removal of the supernatant. No white crystals of  
220 unreacted ibuprofen were observed. The obtained precipitant of final  
221 NPs was placed in the round-bottom glass vessel in a desiccator for  
222 thermal treatment at *T* = 100 ± 1 °C for 5 h until a dry powder was  
223 formed.

224 Control experiments were performed following the abovementioned  
225 protocol of the synthesis in the absence of preformed GO or  
226 Fe<sub>3</sub>O<sub>4</sub> or both of them to obtain ibuprofen-GO, ibuprofen-Fe<sub>3</sub>O<sub>4</sub>, and  
227 pure ibuprofen NPs. Each aqueous solution of GO and Fe<sub>3</sub>O<sub>4</sub> was  
228 used as an "antisolvent" keeping the volume ratio of "solvent:anti-  
229 solvent" as 1:1. For optical phase contrast microscope analysis, freshly  
230 prepared colloidal solutions were deposited on a glass coverslip via the  
231 drop-casting method and allowed for evaporation.

232 **2.2. Equipment and Analytical Methods.** The synthesized  
233 materials were characterized by using the following methods:  
234 transmission electron microscopy (TEM), scanning electron micros-  
235 copy (SEM), energy dispersive X-ray fluorescence (EDX), X-ray  
236 powder diffraction (XRD), UV-visible absorbance spectroscopy,  
237 Fourier-transform infrared (FTIR) spectroscopy, and confocal Raman  
238 microscopy, time-of-flight secondary-ion mass spectrometry (TOF  
239 SIMS), and optical phase contrast microscopy.

240 The visualization of the inner and surface composition of prepared  
241 materials was performed by TEM (LEO-906E) Carl Zeiss, Germany.  
242 The morphology and elemental composition of synthesized products  
243 were characterized by SEM (S-4800) Hitachi, Japan. The phase  
244 composition, crystalline structure, and crystallite size of synthesized  
245 materials were determined by using powder diffraction patterns  
246 recorded with X-ray diffractometer Alosa Group using Co *Kα*  
247 radiation at λ = 1.79 Å (Ni-filter) at 296 K with a scan step 0.005 and  
248 rate 0.1/min. Crystallite size *t* was determined by applying Scherrer's  
249 [formula 1](#) to the most intensive plane (311) in the XRD pattern:

$$t = \frac{k\lambda}{\beta \cos \theta_B} \quad (1)$$

251 where *k* is the constant depending on the crystallite shape (*k* = 0.89  
252 for GO and Fe<sub>3</sub>O<sub>4</sub>), λ is the X-ray wavelength (Co *Kα* = 1.79 Å), β is  
253 the integral breadth or full width at half-maximum, and θ<sub>B</sub> is the Bragg  
254 angle. The most intense diffraction reflexes at 2θ<sub>B</sub> = 36.22° for Fe<sub>3</sub>O<sub>4</sub>  
255 with β = 0.325 were used to calculate *t* values.

256 The electronic molecular properties of colloidal solutions were  
257 analyzed by UV-visible absorbance spectroscopy. The UV-visible  
258 absorbance spectra of colloidal solutions were recorded by using a  
259 PROSCAN spectrophotometer MC-122 (Belarus) operating with  
260 deuterium and halogen lamps in the wavelength ranges from 190 to  
261 365 nm and from 330 to 1100 nm. For measurements, colloidal

solutions were placed in a quartz (SUPRASIL) cuvette Hellma 262  
Analytics (Germany) 111-QS (Z600725) with a path length of 10 263  
mm. 264

The identification of chemical groups and bonds present in 265  
synthesized nanoparticles was performed with the use of Fourier- 266  
transform infrared (FTIR) spectroscopy. FTIR spectra of synthesized 267  
powders were recorded by using a Bruker Alpha II FTIR spectrometer 268  
(USA) with a diamond crystal attenuated total internal reflectance 269  
(ATR) accessory. FTIR spectra were acquired in the wavenumber 270  
range from 4000 to 400 cm<sup>-1</sup> (spectral resolution 2 cm<sup>-1</sup>) by applying 271  
a suspension method of powders in KBr. A powder of synthesized 272  
materials was thoroughly ground with a dehydrated KBr at a weight 273  
ratio of 1:800 followed by pressing this mixture at ~10 ton/mg into 274  
thin transparent spherical disks. 275

The surface molecular structure of synthesized materials was 276  
characterized by Raman spectroscopy. Raman spectra of colloids were 277  
recorded by using a laser 3D scanning confocal microscope Confotec 278  
NR500 (Belarusian-Japanese joint venture "SOLAR TII") at 473 nm 279  
excitation wavelength with a grating 600 gr/mm blazed at 600 nm. 280  
The Si wafer with the characteristic Raman line at 520 cm<sup>-1</sup> was taken 281  
as a reference for calibration and basic alignment during integration 282  
time from 3 to 50 s. The acquired Raman spectra were corrected for 283  
the baseline. A linearly polarized diode laser beam was focused 284  
through the objectives with 40× or 100× magnification for Raman 285  
spectra acquisition. The laser power was attenuated by using neutral 286  
density filters with the following OD values 0.6 (25), 0.3 (50), and no 287  
filter (100). 288

The elemental and molecular composition of nanoparticles was 289  
determined via acquisition of the mass/charge patterns in the use of a 290  
time-of-flight TOF.SIMS 5 secondary-ion mass spectrometer 291  
(IONTOF GmbH, Germany). For measurements, Si wafers were 292  
first purified by wet chemical cleaning method with the use of 293  
isopropanol, DI water, and ethanol. Second cleaned Si wafers were 294  
coated by a thin homogeneous layer of nanoparticles via the drop- 295  
casting procedure. SIMS measurements were performed by applying 296  
an Ar ion source in a static mode to keep the primary ion flux to a 297  
level that fragments a maximum of 1–10% of the coating surface with 298  
a spatial resolution ~100 nm and a sampling depth of <2 nm. 299


230 **2.2.1. Morphological Stability of Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nano-**  
231 **spheres.** The stability of prepared colloids and crystallization of 301  
ibuprofen were monitored by optical phase contrast microscopy via 302  
direct observation and recording by a high speed camera connected to 303  
an optical light microscope Planar MKI-2 M (Belarus) through taking 304  
photographs in real time and characterized by Software imaging tool 305  
ScopeTek Photo 3.1.312 (×86) of samples coated on glass coverslips. 306  
In experiments, the microscope objective was used with the aperture/ 307  
focus 0.08/48 and the resolution 936 px in 0.1 mm. 308

232 **2.2.2. Catalytic Activity of Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nanospheres.** 309  
The electron-transfer reaction between 0.01 M Fe(CN)<sub>6</sub><sup>3-</sup> and 0.1 M 310  
S<sub>2</sub>O<sub>3</sub><sup>2-</sup> at a volume ratio of 1:1 was chosen to examine the 311  
electrokinetic activity of 600 μL ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres in 312  
comparison with pristine ibuprofen. The absorbance spectra of 313  
aqueous colloidal solutions were measured with the use of a 314  
PROSCAN MC-122 spectrophotometer (Belarus) with an operating 315  
range from 190 to 1100 nm at a step 1 nm, wavelength setting 316  
accuracy: ± 0.2 nm and reproducibility ±0.1 nm at 25 ± 1 °C. The 317  
decline of the Fe(CN)<sub>6</sub><sup>3-</sup> peaks with and without nanoparticles was 318  
monitored by the absorbance at ~420 nm as a function of time. The 319  
kinetics of the electron transfer during this reaction were examined 320  
every 5 min of reaction. Always freshly prepared hexacyanoferrate 321  
(III) and thiosulfate aqueous solutions were used in each kinetic run. 322

233 **2.2.3. Electrochemical Measurements (the Electro-Fenton**  
234 **Process).** The Fenton reaction, i.e., iron-catalyzed H<sub>2</sub>O<sub>2</sub> decom- 323  
position, was chosen to examine the formation of OH and ·OH 324  
radicals via the process of H<sub>2</sub>O<sub>2</sub> decomposition catalyzed by iron 325  
cations Fe<sup>2+</sup> at the contact with the synthesized colloids. In an 326  
experiment, 5 mM FeCl<sub>2</sub> (used as a catalyst) in DI water and 100 mM 327  
Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O (used as a phosphate-buffered solution, pH 9) in DI 328  
water were mixed at a volume ratio of 1:1. This mixture was added by 329  
H<sub>2</sub>O<sub>2</sub> (50 wt %) at a volume ratio of 1:1:1.5 acidified by few drops of 330  
331



**Scheme 1. Schematic Illustration Demonstrating the Principle of Ultrasonic Complexation (at 20 KHz) of Pristine Ibuprofen with Fe<sub>3</sub>O<sub>4</sub>-GO Nanoplatfom via the Formation of Ibuprofen-Fe(II), Ibuprofen-Fe-O, and Ibuprofen-C-O-Fe Bonds in Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nanospheres with a Core-Shell Structure in the Frame of the Acoustic Emulsification Mechanism of a Biphasic “Solvent:Antisolvent” Mixture**



332 H<sub>2</sub>SO<sub>4</sub> (93.6 wt %, pH 4.5) to perform the electro-Fenton process in  
333 a final volume of 35 mL in a glass vessel.

334 The Fenton reaction was carried out with the use of a three-  
335 electrode system consisting of working and counting electrodes as  
336 graphite paper sheets with the geometrical size 43 × 17 mm and a  
337 reference Ag/AgCl electrode. A stock 3.19 mol/L KCl aqueous  
338 solution was used as a supported electrolyte. Electrochemical  
339 measurements (cyclic voltammetry) were performed with the  
340 Metrohm Autolab potentiostat/galvanostat instrument operating  
341 with the Nova 1.11 software allowing data acquisition and analysis.

342 Electrochemical experiments were carried out by adding 1 × 10<sup>-3</sup> L  
343 of free ibuprofen (in ethanol solution) or synthesized nanospheres in  
344 aqueous solution in the total volume of 5 × 10<sup>-3</sup> L during the  
345 electrochemical process of 10 scans at scan rate 0.1 V/s in the applied  
346 voltage range from -0.5 to +1.2 V.

### 3. RESULTS AND DISCUSSION


347 In this work, we demonstrate the principle of functionalization  
348 of pristine ibuprofen via ultrasonic complexation at the contact  
349 with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom through the formation of  
350 ibuprofen-Fe(II), ibuprofen-Fe-O and ibuprofen-C-O-Fe  
351 bonds by applying the “solvent:antisolvent” precipitation  
352 technique. Acoustic emulsification is used as a tool for a  
353 biphasic mixture consisting of pristine ibuprofen in ethanol  
354 solution (“solvent”) and aqueous colloidal Fe<sub>3</sub>O<sub>4</sub>-GO solution  
355 (“antisolvent”) to prepare ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres  
356 with a core-shell structure as shown in Scheme 1.

357 The ultrasonic complexation of pristine ibuprofen takes  
358 place at the ethanol:water interface under ultrasound (20 kHz)  
359 that induces emulsification of two fluids “solvent:antisolvent”  
360 in a single-step procedure. Our method of ultrasonic  
361 complexation is based on the acoustic emulsification of a  
362 biphasic mixture consisting of a “solvent” as a nonpolar liquid  
363 and an “antisolvent” as a polar liquid. The main parameters of  
364 fluids in this process are the density  $\rho$  and viscosity  $\eta$  of liquids,  
365 and speed  $v$  of sound in these liquids, while the volume  
366 fraction and the order of addition of one liquid into the other  
367 along with the acoustic pressure amplitude will determine the  
368 final size of obtained droplets according to a two-step  
369 mechanism of acoustic emulsification proposed by H.S. Folger  
370 and his colleagues in 1978. In this way, the first stage of  
371 acoustic emulsification is the formation of large droplets by the  
372 rupture of waves on a planar “solvent:antisolvent” interface. In  
373 the second stage, the large droplets are continually broken into  
374 smaller droplets by the shock waves emanating from the  
375 collapse of cavitation bubbles.

376 In our experiments, the density of “antisolvent” (density of 376  
377 magnetite  $\sim 5170$  kg/m<sup>3</sup> and water  $\sim 1000$  kg/m<sup>3</sup> at  $T = 20$   
378 °C) is larger than the density of “solvent” (density of ethanol 378  
379  $\sim 789$  kg/m<sup>3</sup> at  $T = 20$  °C and ibuprofen at 5 mM  $\sim 1.0$  kg/m<sup>3</sup>  
380 and at 25 mM  $\sim 5.2$  kg/m<sup>3</sup> at  $T = 20$  °C). As the density of 380  
381 “solvent” is relatively low, the intensity of ultrasound is higher  
382 in it than in “antisolvent” which is determined by the following  
383 equation  $I = P_A^2/2\rho v$ , where  $P_A$  is the maximum pressure  
384 amplitude,  $\rho$  is the density of a liquid, and  $v$  is the speed of 384  
385 sound in this liquid. We can consider the kinematic viscosity,  
386 which is defined as  $\eta = \mu/\rho$ , where  $\mu$  is the dynamic viscosity  
387 and  $\rho$  is the density of the fluid, the ratio of viscosity  
388 magnitudes of “solvent” to “antisolvent”, i.e.,  $\eta_{\text{sol}}:\eta_{\text{antisol}}$  is  $\sim 7.8$ .  
389 Therefore, the propagation of sound waves in “solvent” is  
390 easier and faster because of the higher intensity of ultrasound  
391 in contrast to the “antisolvent” phase, which acts rather as an  
392 acoustic impedance at 20 kHz and constant acoustic pressure  
393 amplitude.

394 Taking into consideration all these parameters of two liquid  
395 phases: “solvent” and “antisolvent”, we can define the  
396 approximate size of initial large particles as of  $\sim 37$   $\mu\text{m}$   
397 because of the amplitude of the irradiating and vibrating horn,  
398 which determines the disruption of the planar interface formed  
399 between these two phases according to the type of Rayleigh-  
400 Taylor instability mechanism. By definition, the Rayleigh-  
401 Taylor instability mechanism occurs between two fluids of  
402 different densities, when the lighter fluid is pushing the heavier  
403 one. In our case, the solvent is pushing the antisolvent by the  
404 Rayleigh-Taylor instability mechanism. The equilibrium of  
405 this biphasic “solvent:antisolvent” mixture is unstable to any  
406 perturbations or disturbances of the interface, which has a  
407 lower potential energy in comparison with the initial state of  
408 the two fluids. In this way, the more dense “antisolvent” phase  
409 is dispersed into the less dense and more viscous “solvent”  
410 phase, which basically should coat the surface of “antisolvent”  
411 drops in the biphasic mixture. As a result of it, ibuprofen-  
412 Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres with a distinct core-shell structure  
413 can be formed.

414 It is more probable that such a core-shell structure is  
415 formed at the first step of acoustic emulsification. The short  
416 duration of sonication (3 min) is sufficient for the drops  
417 (particles) to break up into very small particles, which is  
418 determined rather by the density and viscosity magnitudes of  
419 fluids and a high intensity of applied acoustic field. One more  
420 argument, the higher hydrophobicity of the “solvent” phase



**Figure 1.** Representative (a) SEM and (b) TEM images of synthesized ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres are shown with (c) statistical diagram of the average size distribution of dark particulates per surface area (nm<sup>2</sup>) that form larger assemblies. (d) Raman spectra of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO and Fe<sub>3</sub>O<sub>4</sub> NPs, Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatform, and pristine ibuprofen are shown ( $\lambda_{\text{exc}} = 473$  nm). (e) UV-vis absorbance spectra of aqueous colloidal solutions of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO and ibuprofen-GO and free ibuprofen per se (81 wt %) are demonstrated. The inset scheme shows the changes of the ibuprofen molecular structure according to the observed characteristic absorbance bands indicating hydrogen atom abstraction, modified phenyl ring, and complexation of the carboxyl group with Fe (at 218 nm).

421 may lead ibuprofen and ethanol molecules to be adsorbed at  
 422 the cavitation interface being able to penetrate the hot gaseous  
 423 bubble interior upon implosive collapse and directly experience  
 424 the shock waves emanating to the distance of  $\sim 200$  nm from the  
 425 center of the hot spot. This scenario is realistic according to  
 426 the nanodroplet injection model of cavitation bubbles, which  
 427 was experimentally proved by the group of Prof. K.S. Suslick.

428 Let us examine the electronic-molecular properties of  
 429 ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres through the study of  
 430 individual components such as GO and Fe<sub>3</sub>O<sub>4</sub> at the contact  
 431 with ibuprofen in comparison with pristine drug molecules to  
 432 understand the ultrasonic complexation mechanism.

433 **3.1. Ultrasonic Complexation of Ibuprofen with the**  
 434 **Fe<sub>3</sub>O<sub>4</sub>-GO Nanoplatform.** At first, we synthesized small GO  
 435 colloids with a uniform structure by applying the second  
 436 oxidation procedure according to the improved Hummers  
 437 protocol (more details in [Supporting Information](#)). Prepared  
 438 GO material has a C/O ratio  $\sim 1.49$ , which is lower than that  
 439 of GO from the first oxidation step ( $\sim 1.83$ ), indicating  
 440 enhanced oxidation of graphene sheets and formation of  
 441 oxygen functional groups ([Figure S1](#)). This GO was used for  
 442 the synthesis of Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatform, which appeared in  
 443 the form of nonuniform spheres of average size ( $26.9 \pm 7.1$ )  
 444 nm with a thin layer coating of the following elemental  
 445 composition (at %): O ( $48.1 \pm 2.7$ ), Fe ( $43.1 \pm 2.1$ ), C ( $8.6 \pm$   
 446  $0.6$ ) (incl. Cl  $\sim 0.14$ ) and C/O ratio of  $\sim 0.18$  ([Figure S2](#)).


447 Acoustic emulsification of a biphasic mixture consisting of  
 448 ethanolic solution of pristine ibuprofen (“solvent”) and  
 449 aqueous colloidal solution of Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatform  
 450 (“antisolvent”) leads to the formation of final ibuprofen-  
 451 Fe<sub>3</sub>O<sub>4</sub>-GO nanoparticles with a spherical shape and a distinct  
 452 core-shell structure ([Figure 1a,b](#)). The core of final ibuprofen-  
 453 Fe<sub>3</sub>O<sub>4</sub>-GO nanoparticles consists of small dark particulates

with an average size  $14.91 \pm 0.17$  nm that form an assembly of  
 454 a larger size  $\sim 50.81 \pm 0.23$  nm ([Figure 1c](#)). This dark core is  
 455 coated by a gray shell with a thickness  $\sim 14.0$  nm. Careful study  
 456 of TEM images of these nanoparticles revealed their porous  
 457 inner structure with two distinct regions: a black core and a  
 458 gray shell in contrast to produced pristine ibuprofen NPs  
 459 ([Figure S3](#)).

460  
 461 **3.2. Surface Molecular Composition of Ibuprofen-**  
 462 **Fe<sub>3</sub>O<sub>4</sub>-GO.** The surface molecular composition of formed  
 463 ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres was determined by Raman  
 464 spectroscopy via comparison with Raman spectra of free  
 465 ibuprofen per se, Fe<sub>3</sub>O<sub>4</sub>, and Fe<sub>3</sub>O<sub>4</sub>-GO NPs ([Figure 1d](#)).  
 466 Raman spectra of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres show a  
 467 characteristic peak of iron oxide with the magnetite phase at  
 468  $576$  cm<sup>-1</sup>, D band at  $\sim 1355$  cm<sup>-1</sup> caused by amorphization  
 469 and oxidation of graphitic nanocrystals<sup>49</sup> and the G band at  
 470  $\sim 1590$  cm<sup>-1</sup> of GO with sp<sup>2</sup>-bonded carbon atoms consisting  
 471 of distorted 6-fold rings or rings of other orders,<sup>50</sup> and peaks of  
 472 ibuprofen at  $268$ ,  $378$ , and  $477$  cm<sup>-1</sup>,<sup>51,52</sup> which confirms the  
 473 formation of magnetite-graphene structure in the complex with  
 474 ibuprofen.

475 Raman spectra of the Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatform reveal the  
 476 band of Fe<sub>3</sub>O<sub>4</sub> at  $\sim 337$  cm<sup>-1</sup>, and vibrations of Fe-O ( $\sim 492$   
 477 cm<sup>-1</sup>) and Fe<sub>3</sub>O<sub>4</sub> ( $\sim 667$  cm<sup>-1</sup>),<sup>53</sup> indicating the formation of  
 478 Fe<sub>3</sub>O<sub>4</sub> NPs on the surface of GO. The intensity ratio of D and  
 479 G bands Int(D)/Int(G) is  $\sim 0.83$  in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO  
 480 nanospheres and  $\sim 0.95$  in Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatform, indicating  
 481 the lower density of defects in nanospheres.

482 For comparison, Raman spectra of Fe<sub>3</sub>O<sub>4</sub> NPs stabilized  
 483 with citric acid ligands reveal the iron oxide phase with an  
 484 organic coating by citrate ligands caused by laser-induced  
 485 oxidation ( $\sim 337$  cm<sup>-1</sup>)<sup>53</sup> and demonstrate the formation of  
 486 Fe-O-Fe ( $\sim 500$  cm<sup>-1</sup>)<sup>54</sup> bonds and Fe<sub>3</sub>O<sub>4</sub> ( $\sim 682$  cm<sup>-1</sup>)



**Figure 2.** (a) Fourier-transform infrared transmittance spectra of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO, Fe<sub>3</sub>O<sub>4</sub>-GO and GO nanoparticles in comparison with ibuprofen per se are shown. (b) Schematic illustration shows a chemical structure of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres indicating the formation of Fe–O and Fe–OH bonds between ibuprofen and GO with the magnetite phase. (c) X-ray powder diffraction patterns of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres are shown in comparison with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplateform, GO and ibuprofen per se.

487 phase.<sup>55</sup> Vibrational modes at  $\sim 1387$  and  $\sim 1559$  cm<sup>-1</sup> can be  
 488 assigned to the magnetite phase at the nanoscale with the  
 489 surface coated by citrate ligands under oxidation induced by  
 490 laser excitation<sup>56</sup> as compared with the reference of Raman  
 491 spectrum of bulk magnetite (Figure S4).

492 **3.3. Electronic Molecular Structure of Ibuprofen-**  
 493 **Fe<sub>3</sub>O<sub>4</sub>-GO Nanospheres.** The electronic molecular structure  
 494 of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres was assessed by UV–vis  
 495 absorbance spectroscopy (Figure 1e). The UV–vis absorbance  
 496 spectrum of an aqueous solution of these nanospheres is  
 497 manifold with one distinct peak at  $\sim 218$  nm and the series of  
 498 smaller peaks at  $\sim 233$ , 243, 262, 273, 285, 295, and 305 nm on  
 499 an elevated continuum, indicating complex electronic  
 500 ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO structure, in which the chromophore of  
 501 ibuprofen can be located within the surface layers of  
 502 nanospheres. To understand this complexity of nanospheres,  
 503 let us refer to the pristine ibuprofen (absolute ethanol solution,  
 504 pH 5.5), which absorbs light at  $\sim 222$ , 233, and 264 nm as a  
 505 result of the electronic  $\pi$ – $\pi^*$  transitions of its modified phenyl  
 506 group and the electronic transitions of ibuprofen  $\pi_{PY} \rightarrow \pi_{CO}^*$   
 507 occurring between the phenyl ring and C–O bonds caused by  
 508 oxidation of hydroxyl radicals.<sup>57</sup>

509 Ultrasonic complexation of ibuprofen with GO leads to the  
 510 enhancement of absorbance at  $\sim 222$  nm and disappearance of  
 511 band at  $\sim 233$  nm, indicating the decreased concentration of  
 512 protonated species, which exhibit the first vertical S1 excitation

(HUMO  $\rightarrow$  LUMO) of  $\pi$ – $\pi^*$  nature.<sup>58</sup> In an aqueous solution 513  
 of ibuprofen-GO NPs (50 wt %, pH 5.5) the strong band at 514  
 $\sim 264$  nm becomes broad with much lower intensity than in 515  
 pristine ibuprofen, which is indicative for the substitution in 516  
 the side chains of the drug molecular structure within the 517  
 modified phenyl ring.<sup>59</sup> 518

Therefore, ultrasonic complexation of pristine ibuprofen 519  
 with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplateform involves abstraction of a 520  
 hydrogen atom by 'OH radicals forming the methylbenzyl<sup>57</sup> 521  
 and other benzyl type and hydroxycyclohexadienyl type 522  
 radicals due to  $\pi$ – $\pi^*$  transitions. The bathochromic shift of 523  
 a band in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres in high energy 524  
 region from 210 to 215 to 218 nm indicates the formation of a 525  
 complex between Fe and carboxyl group of ibuprofen due to  $n$ - 526  
 $\pi^*$  transitions, which can be caused by the charge transfer 527  
 reaction between the drug ligands and iron atoms in Fe<sub>3</sub>O<sub>4</sub>- 528  
 GO or due to the formation of ion-pair complexes. The 529  
 appearance of a small band at  $\sim 243$  nm is caused by the shift 530  
 of a band at  $\sim 264$  to  $\sim 262$  nm accompanied by the appearance 531  
 of multiple smaller peaks up to 305 nm, demonstrating that 532  
 hydroxylation may take place in the side chains and also in the 533  
 ring of ibuprofen as a result of reaction with 'OH radicals.<sup>59</sup> 534  
 The absorbance band of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres at 535  
 $\sim 273$  nm is caused by the interaction of ibuprofen with 536  
 ethanol. The relatively low intensity of a band at  $\sim 285$  nm 537  
 points out to the domination of the hydroxycyclohexadienyl 538

**Table 1.** Analysis of Experimental X-ray Powder Diffraction  $2\theta$  (deg) Values Is Shown with Calculated Interplanar Spacing  $d$  (nm) Magnitudes of GO, Fe<sub>3</sub>O<sub>4</sub>-GO Nanoplatfom, and Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nanospheres (Co  $K_{\alpha}$  = 1.79 Å)

material	$2\theta$ (deg)	int. (a.u.)	$d$ (nm)	(hkl)	assignment	
GO	11.73	100	0.876	(001)	GO	
	24.53	82	0.421	(003)	GO	
ibuprofen-Fe <sub>3</sub> O <sub>4</sub> -GO	11.85	1	0.866	(001)	GO	
	24.78	100	0.417	(003)	GO	
	35.12	67	0.297	(220)	Fe <sub>3</sub> O <sub>4</sub>	
	39.00	61	0.268	(004)	GO	
	41.43	86	0.253	(311)	Fe <sub>3</sub> O <sub>4</sub>	
	50.64	59	0.209	(400)	Fe <sub>3</sub> O <sub>4</sub>	
	63.41	52	0.170	(422)	Fe <sub>3</sub> O <sub>4</sub> *	
	67.90	58	0.160	(511)	Fe <sub>3</sub> O <sub>4</sub> *	
	74.52	61	0.148	(440)	Fe <sub>3</sub> O <sub>4</sub>	
	Fe <sub>3</sub> O <sub>4</sub> -GO	35.20	44	0.296	(220)	Fe <sub>3</sub> O <sub>4</sub>
		38.69	33	0.270	(004)	GO
41.51		100	0.253	(311)	Fe <sub>3</sub> O <sub>4</sub>	
50.71		41	0.209	(400)	Fe <sub>3</sub> O <sub>4</sub>	
63.49		36	0.170	(422)	Fe <sub>3</sub> O <sub>4</sub>	
67.60		48	0.161	(511)	Fe <sub>3</sub> O <sub>4</sub>	
74.60		58	0.148	(440)	Fe <sub>3</sub> O <sub>4</sub>	

type radicals and formation of hydroxylated products in the ring. Therefore, it can be concluded that the carboxyl group of ibuprofen, which is directly involved in the complex formation with iron, and the oxidized form of the phenyl group contribute to the increase of the electron density of ibuprofen within the Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom.

**3.4. Chemical Bond Formation between Ibuprofen, Fe<sub>3</sub>O<sub>4</sub>, and GO.** Next, ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres were characterized by the use of FTIR spectroscopy to understand the chemical bond formation between ibuprofen, Fe<sub>3</sub>O<sub>4</sub>, and GO (Figure 2a). The analysis of bands from FTIR transmittance spectra of pristine ibuprofen (Table S1), GO, Fe<sub>3</sub>O<sub>4</sub>-GO, and ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres are shown in Tables S2–S4 (Supporting Information). FTIR spectrum of GO shows characteristic modes of  $\nu$ (C–S) ( $\sim$ 712 cm<sup>-1</sup>), C–O vibrations of epoxide groups ( $\sim$ 873 cm<sup>-1</sup>, 1021–1220 cm<sup>-1</sup>),  $\nu$ (COO<sup>-</sup>) and C=O of carboxyl and carbonyl groups ( $\sim$ 1426 cm<sup>-1</sup>, 1735 cm<sup>-1</sup>), deformation of water molecules intercalated in oxidized graphitic domains ( $\sim$ 1625 cm<sup>-1</sup>), aliphatic C–H stretching (2852 and 2923 cm<sup>-1</sup>) and adsorbed water molecules, hydroxyl and carboxyl groups ( $\sim$ 3190 and 3423 cm<sup>-1</sup>) (Table S2). Therefore, synthesized GO consists of hydroxyl, carboxyl, and epoxide groups with the presence of large aromatic regions and is free of bisulfate, O<sub>3</sub>S–OH, O=S=O, –SO<sub>3</sub>, and H<sub>3</sub>O<sup>+</sup> groups, which is indicative for high-purity GO nanosheets.<sup>60</sup> FTIR spectra of Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom show a distinct band at  $\sim$ 538 cm<sup>-1</sup> and two shoulders near  $\sim$ 624 and 685 cm<sup>-1</sup>, which can be assigned to Fe<sub>3</sub>O<sub>4</sub> after oxidation caused by either elevated temperature<sup>61</sup> or by the interaction with GO according to the proposed dynamic structural model with migrating oxygen functional groups<sup>62,63</sup> (Table S3).


In ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO, the fundamental Fe–O vibration is upshifted from 538 to 560 cm<sup>-1</sup> and develops a shoulder at 687 cm<sup>-1</sup>, which is indicative for Fe<sub>3</sub>O<sub>4</sub> with adsorbed hydroxyl groups caused by oxidation at the contact with GO and ibuprofen during acoustic emulsification (Table S4). The vibrational displacement of oxygen atoms in C–O of GO (according to the dynamic structural model) confirms the enhanced oxidation of the NPs surface.

In ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres, ibuprofen exhibits C–H bending, CH<sub>2</sub> twisting, and CH<sub>3</sub> rocking at  $\sim$ 1074 cm<sup>-1</sup>, CO–H in-plane bending (H-bonded) at  $\sim$ 1231 cm<sup>-1</sup>, C–H bending, C–C–O stretching and CO–H bending at  $\sim$ 1370 cm<sup>-1</sup>, ring vibration and CH<sub>3</sub> antisymmetric deformation at  $\sim$ 1452 cm<sup>-1</sup> and C=O stretching (H-bonded) at  $\sim$ 1721 cm<sup>-1</sup>, CH<sub>3</sub> out of phase symmetric stretching at  $\sim$ 2918 cm<sup>-1</sup>, pointing out to the specific complexation of drug ligands through the H-bond formation with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom. The observed  $\nu$ (COO<sup>-</sup>) asymmetric stretch of the carboxyl group at  $\sim$ 1577 cm<sup>-1</sup> in Fe<sub>3</sub>O<sub>4</sub>-GO is strongly enhanced in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres, confirming the complexation of ibuprofen with nanoplatfom (Figure 2b). Therefore, one may conclude that the side chains of ibuprofen such as CH, CH<sub>2</sub>, and CH<sub>3</sub> can form H-bonds with C–O–H and involve the interaction of carboxylic groups with Fe–O bonds in Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom bearing surface adsorbed OH groups.

**3.5. Crystalline Structure of Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO.** The crystalline structure of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres was examined by X-ray powder diffraction in comparison with patterns of pristine ibuprofen (Table S5), GO and Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom (Figure 2c and Table 1). The XRD pattern of GO in a solvent-free state shows two distinct reflexes at  $2\theta = 11.73^\circ$  and  $24.53^\circ$  with the interplanar spacing values  $\sim$ 8.759 Å and  $\sim$ 4.215 Å, which can be assigned to (001) and (003) of GO.<sup>64</sup> The interplanar spacing of the (001) plane is 0.779 Å higher than in graphite intercalation compound ( $\sim$ 7.980 Å) during the process of GO formation, which is indicative of the intercalation of oxygen atoms in the forming oxidized domains. On the other hand, the  $d \sim$ 8.759 Å of (001) is comparable to the lattice expansion of (001) in GO caused by intercalation of 1-propanol ( $\sim$ 8.650 Å). The  $2\theta$  peak at  $\sim$ 24.53° indicates the heterogeneous nature of GO that contains carbon domains with sp<sup>2</sup>- and sp<sup>3</sup> hybridization. The crystallite size of synthesized GO is  $\sim$ 7.41 Å ( $2\theta = 24.53^\circ$ ,  $\beta = 0.22$ ), which corresponds to  $\approx$ 2 layers of graphene assuming the van der Waals diameter of carbon  $\sim$ 3.45 Å.<sup>64</sup>

The interplanar spacing values of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres are comparable with the Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfom





**Figure 3.** Optical phase contrast microscopy images of pristine ibuprofen spheres and their average diameter distribution histograms before (a,b) and after 24 h of aging (c,d); ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO spheres before (e,f) and after of 24 h of aging (g,h) are shown (scale bar is 10 μm). The initial concentration of ibuprofen per se in all experiments was 25 mmol/L.

619 revealing GO, and the phases of graphite-diamond inter-  
 620 mediate and magnetite (Table 1), but not of ibuprofen per  
 621 se.<sup>65</sup> The XRD reflexes of ibuprofen per se can be assigned to  
 622 the crystalline structure of rac-ibuprofen form II in a hydrated  
 623 state<sup>66</sup> (Table S5). The XRD pattern of the Fe<sub>3</sub>O<sub>4</sub>-GO  
 624 nanoplatform shows characteristic reflexes of GO and Fe<sub>3</sub>O<sub>4</sub>  
 625 obtained at ~1.55 GPa.<sup>67</sup> In the XRD pattern of ibuprofen-  
 626 Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres, most of the reflexes indicate pure  
 627 magnetite phase<sup>24</sup> except the interplanar spacing values of  
 628 (422) and (511), which are decreased and can be assigned to  
 629 the high-pressure effect of ~4.99 GPa on Fe<sub>3</sub>O<sub>4</sub>.<sup>68</sup> Such high  
 630 pressure can cause the reduction of the interplanar spacing  
 631 values of GO from 0.876 to 0.866 nm, from 0.421 to 0.417 nm,  
 632 and graphite-diamond intermediate from 0.270 to 0.268 nm.  
 633 Under such conditions, the H-ordering in carboxylic acids can  
 634 be affected by increasing the intermolecular interactions  
 635 involving the carboxyl oxygen atoms and by compressing the  
 636 O...O distances, resulting in a decrease of the potential-energy  
 637 barrier between the H-sites, facilitating the H-disordering.<sup>69</sup>

638 **3.6. Colloidal Stability of Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nano-**  
 639 **spheres.** The colloidal stability of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO  
 640 nanospheres was examined by optical phase contrast  
 641 microscopy (Figure 3). Microscopic images reveal mono-  
 642 disperse spherical pristine ibuprofen NPs with an average  
 643 diameter  $\langle d \rangle = (2.90 \pm 0.07) \mu\text{m}$  that form a uniform coating  
 644 on the glass coverslip (Figure 3a,b).

645 After 24 h of aging in a mother solution, the average  
 646 diameter of these NPs became smaller  $\langle d \rangle = (2.41 \pm 0.21)$   
 647  $\mu\text{m}$ , and its distribution histogram became broader demon-  
 648 strating an increased amount of NPs with larger diameters up  
 649 to ~20 μm (Figure 3c,d). Therefore, one may assume that  
 650 after 24 h NPs increased their diameter including the minority  
 651 of smaller NPs with the initial  $\langle d \rangle$  less than ~2.9 μm. In  
 652 contrast, the average diameter of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nano-  
 653 spheres  $\langle d \rangle = (2.72 \pm 0.04) \mu\text{m}$  (Figure 3e,f) increased up to  
 654  $3.45 \pm 0.04 \mu\text{m}$  (Figure 3g,h) and the largest detected

diameter of spheres did not exceed ~8 μm. All types of NPs  
 655 preserved their spherical shape. In this way, complexation of  
 656 ibuprofen with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatform significantly slows  
 657 down the growth of spheres in comparison with pristine  
 658 ibuprofen NPs.  
 659


### 3.7. Catalytic Activity of Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nano-

660 **spheres.** The catalytic activity in the inhibition of ·OH radical  
 661 formation on the surface of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres  
 662 was examined in comparison with ibuprofen per se (81 wt %)   
 663 and pristine ibuprofen NPs in the electro-Fenton process  
 664 (Figure 4). The formation of ·OH radical is associated with the  
 665 characteristic current peaks at ~4.86 mA (~0.45 V) due to  
 666 oxidation and at ~-4.66 mA (~0.15 V) due to reduction,  
 667 indicating the reversible electro-Fenton process (Figure 4a).  
 668 Soon after the introduction of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nano-  
 669 spheres in the Fenton reaction system, current peaks  
 670 diminished in a concentration-dependent manner of com-  
 671 plexed ibuprofen. In particular, the oxidation peak of ·OH  
 672 radicals disappeared at a rate ~of  $2.7 \times 10^3$ , when the  
 673 concentration of ibuprofen in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nano-  
 674 spheres increased from 41.15 to 205.75 μg/mL, demonstrating  
 675 the radical scavenging ability of complexed ibuprofen (Figure  
 676 4b). In a reversible redox cycle the current reduction peak also  
 677 disappeared, indicating that the contribution of reaction  
 678 products such as H<sup>+</sup>, O<sub>2</sub>, and H<sub>2</sub>O molecules became less.  
 679

680 The cyclic voltammograms reveal that no oxidation of  
 681 ibuprofen occurred because the characteristic oxidation peak at  
 682 ~+1.2 ± 0.2 V did not appear, meaning that no transfer of an  
 683 electron takes place and no radical-cation (in oxidation) or  
 684 radical-anion (in reduction) of ibuprofen is formed as a result  
 685 of a decarboxylation process.<sup>70</sup> In this way, the scavenging  
 686 efficiency of either complexed or free ibuprofen molecules is  
 687 not associated with the reported toxicity of ibuprofen.

688 The decrease of current peaks in the electro-Fenton process  
 689 was observed in the reaction systems containing free ibuprofen  
 690 per se (Figure 4c) or pristine ibuprofen NPs (Figure 4e) but at





**Figure 4.** Cyclic voltammograms show the relative response of current  $I$  (mA) in aqueous solutions of (a,b) ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO in the concentration range of complexed ibuprofen from 41.15 to 205.75  $\mu\text{g/mL}$ , (c,d) ibuprofen per se (81 wt %, from 19.21 to 96.05  $\mu\text{g/mL}$ ), and (e,f) pristine ibuprofen NPs (from 14.63 to 73.16  $\mu\text{g/mL}$ ) in an applied potential range from  $-0.5$  to  $+1.2$  V and the plots demonstrating the decay of corresponding current peak values of  $\cdot\text{OH}$  formation versus concentration as indicated by a black arrow.


691 slower decay rates  $\sim 113.0$  (Figure 4d) and  $\sim 16.5$  (Figure 4f).  
 692 In this way, the inhibition of  $\cdot\text{OH}$  radicals by ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-  
 693 GO nanospheres is  $\sim 23.5$  times higher than of free ibuprofen  
 694 per se and  $\sim 161.2$  times higher than of pristine ibuprofen  
 695 NPs. In general, the electrochemical oxidation of pristine ibuprofen  
 696 corresponds to the electrochemical-chemical mechanism  
 697 involving the transfer of an electron followed by a  
 698 homogeneous chemical reaction. The mechanism of the  
 699 electrochemical oxidation of ibuprofen is not pH-dependent  
 700 and possibly involves a single electron transfer via radical  
 701 cation formation, followed by decarboxylation. The decreased  
 702 radical scavenging efficiency of noncomplexed ibuprofen may  
 703 be associated with the drug's action as a prooxidant as it is able  
 704 to reduce Fe(III).<sup>16</sup> On the other hand, ibuprofen can form  
 705 iron chelates that lack the free coordination site required for  
 706 iron.<sup>12</sup> However, in contrast to its noncomplexed state,  
 707 complexed ibuprofen in Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres can contain  
 708 chelated iron, thereby providing additional catalytic sites for  
 709 the more efficient inhibition of Fenton oxidation process.

710 **3.8. Antioxidant Mechanism of Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO.**  
 711 From the literature, a chelate, which contains a free  
 712 coordination site and allows iron reactivity, readily combines  
 713 with a substance at a free coordination site, causing a spectral

714 shift. In contrast, a chelate with a compound that decreases  
 715 iron reactivity leaves no coordination site open and shows no  
 716 spectral shift. To test the idea of iron chelation by ibuprofen,  
 717 we studied the electron transfer reaction between Fe(CN)<sub>6</sub><sup>3-</sup>  
 718 and S<sub>2</sub>O<sub>3</sub><sup>2-</sup> at the contact with ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO (4.9  $\mu\text{g}/$   
 719 mL of complexed ibuprofen) and pristine ibuprofen NPs (8.8  
 720  $\mu\text{g}/\text{mL}$  of complexed ibuprofen) and monitored the decline of  
 721 the hexacyanoferrate (III) peaks as a function of time of the  
 722 absorbance band at  $\approx 420$  nm at pH 2.0 and pH 5.5 of aqueous  
 723 colloidal solutions (Figure 5).

724 The UV-vis absorbance spectra of the tested reaction  
 725 colloidal solutions showed a distinct maximum at 300 nm  
 726 ( $\sim 33,333$  cm<sup>-1</sup>) with a shoulder at 320 nm ( $\sim 31,250$  cm<sup>-1</sup>)  
 727 and a peak at 420 nm ( $\sim 23,810$  cm<sup>-1</sup>). The first absorption  
 728 band can be assigned to the <sup>2</sup>T<sub>2g</sub> electronic transitions of  
 729 ferrocyanide ion complexes with spin-allowed  $d \rightarrow d$   
 730 transitions and its shoulder is indicative for the deprotonated  
 731 nitrogen end of cyanide as a result of the destabilized T<sub>2g</sub> level.

732 In aqueous solution of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres at  
 733 pH 2.0, the intensity of the analytical peak at 420 nm  
 734 decreased during the first 15 min of reaction with the  
 735 development of a broad band near 710 nm (Figure 5a). In the  
 736 next 30 min of reaction, the intensity of the analytical band



**Figure 5.** UV-vis absorbance spectra of aqueous solutions of 200  $\mu\text{L}$  of 0.01 M  $\text{Fe}(\text{CN})_6^{3-}$  and 200  $\mu\text{L}$  of 0.1 M  $\text{S}_2\text{O}_3^{2-}$  with 600  $\mu\text{L}$  of ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres at (a) pH 2.0 and (b) pH 5.5 with a local zoom-in peak near 420 nm, and pristine ibuprofen NPs at (d) pH 2.0 and (e) pH 5.5 with a zoom-in peak near 420 nm during 60 min of reaction are shown. Inset plots show the time-dependence evolution of the peak intensity at 420 nm. Plots in (c) and (f) show the experimental data of the peak intensity decay (at 420 nm) after being fitted to the exponential decay function with Pearson's correlation coefficient  $R^2 = 0.99$  and the decay factor  $t_1$  of ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres and pristine ibuprofen NPs.

737 increased with a spectral shift at 440 nm and reached the  
 738 plateau under the overlap of a new broad band with the  
 739 increased continuum (Figure 5a, inset). After an additional 15  
 740 min of reaction, the intensity of the analytical band slightly  
 741 decreased during the growth of a new broad band, which  
 742 showed a spectral shift at 705 nm. The decrease of the  
 743 analytical peak at 420 nm is caused by the electron transfer  
 744 reaction between  $\text{Fe}(\text{CN})_6^{3-}$  and  $\text{S}_2\text{O}_3^{2-}$  as a result of  
 745 oxidation of thiosulfate ions. The band diminishing at 420  
 746 nm after 15 min demonstrates that  $\text{Fe}(\text{CN})_6^{3-}$  had fully  
 747 reacted with  $\text{S}_2\text{O}_3^{2-}$ . The following increase of this absorbance  
 748 band during the next 30 min of reaction can be associated with  
 749 the formation of different protonated species such as  
 750  $\text{HFe}(\text{CN})_6^{2-}$ ,  $\text{H}_2\text{Fe}(\text{CN})_6^-$  or  $\text{H}_3\text{Fe}(\text{CN})_6$ , which is indicative  
 751 of higher  $\text{H}^+$  concentration in aqueous solution. Among these  
 752 protonated species the active form of oxidant was found to be  
 753  $\text{HFe}(\text{CN})_6^{2-}$  which leads to the reaction products such as  
 754 hexacyanoferrate(II) and  $\text{S}_2\text{O}_3^-$ . These changes of the  
 755 analytical absorbance band are accompanied by the spectral  
 756 shift at 440 nm and increase of the broadband near 705 nm,  
 757 indicating mixed charge transfer and ligand field transitions of  
 758 protonated  $\text{Fe}(\text{II})$  complexes of ibuprofen in the close  
 759 proximity of N and phenyl rings.

760 In contrast, in aqueous solution of ibuprofen- $\text{Fe}_3\text{O}_4$ -GO  
 761 nanospheres at pH 5.5, the absorbance peak at 420 nm does  
 762 not shift during 60 min of reaction, but its intensity decreases  
 763 following the exponential decay function  $y = 0.24 + 2.09e^{(-x/t_1)}$   
 764 at a rate  $t_1 = 413.6$  (Figure 5b,c).

765 UV-vis absorbance spectra of pristine ibuprofen NPs at pH  
 766 2.0 show the analytical peak at 420 nm without spectral shift,  
 767 but with the retarded decay of intensity during 60 min of  
 768 reaction, demonstrating the electron transfer between  $\text{Fe}(\text{CN})_6^{3-}$   
 769 and  $\text{S}_2\text{O}_3^{2-}$  without enhanced protonation process  
 770 (Figure 5d). Such a retarded decay is accompanied by a broad  
 771 absorbance band near 720 nm being developed with increased

772 intensity after 60 min of reaction. This band is indicative of the  
 773 low-energy charge transfer absorbance of increased concentration  
 774 of partially or fully deprotonated organic iron-CN  
 775 complexes with phenyl rings. This absorbance band does not  
 776 shift because alkyl groups are longer than methyl groups at the  
 777 bridging nitrogen atom and do not shift the metal-ligand  
 778 charge transfer to lower energy.

779 At pH 5.5, only the analytical peak at 420 nm appears with  
 780 the decreased intensity following the exponential decay  
 781 function  $y = 0.92 + 0.08e^{(-x/t_1)}$  at a rate  $t_1 = 114.3$  during  
 782 60 min of reaction (Figure 5e,f). The electron transfer rate of  
 783 pristine ibuprofen NPs ( $t_1 = 114.3$ ) is  $\sim 3.6$  times lower than  
 784 that of ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres ( $t_1 = 413.6$ ),  
 785 indicating that complexed ibuprofen within  $\text{Fe}_3\text{O}_4$ -GO nano-  
 786 platform is more active in the electron transfer process at pH  
 787 5.5. In this way, we can assume that at low pH ibuprofen in its  
 788 nonionized state forms complexes with  $\text{Fe}_3\text{O}_4$ -GO structure,  
 789 resulting in a free iron coordination site and partial activation  
 790 of iron species in the electron transfer reaction between  
 791  $\text{Fe}(\text{CN})_6^{3-}$  and  $\text{S}_2\text{O}_3^{2-}$ . In contrast, pristine ibuprofen NPs act  
 792 as iron chelators with a closed coordination site, decreasing the  
 793 iron activity at low pH.

794 To prove this assumption, let us consider the nature and  
 795 concentration of positive ionic species on the surface of  
 796 ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres in comparison with free  
 797 ibuprofen per se by using the mass spectrometry method. In  
 798 these experiments, ibuprofen- $\text{Fe}_3\text{O}_4$ -GO nanospheres were  
 799 prepared by mechanical stirring or ultrasound in order to find  
 800 out the effect of ultrasound on complexation of ibuprofen with  
 801  $\text{Fe}_3\text{O}_4$ -GO nanoplatform. The determined concentrations of  
 802 positive ions are listed in Table 2 and the representative mass  
 803 spectra are shown in Figure S5.

804 The calculated concentration of positive ions was  
 805 normalized to the highest concentration of  $\text{H}^+$ . Overall, the  
 806 mass spectra of free ibuprofen per se show the highest

**Table 2. Analysis of Concentration of Positive Ionic Species Formed in Free Ibuprofen Per Se and Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO Nanospheres Determined by the Time-of-Flight Secondary-Ion Mass Spectrometry Method**

intensity of positive ionic species, a.u.	intensity of free ibuprofen per se, a.u.	intensity of ibuprofen-Fe <sub>3</sub> O <sub>4</sub> -GO (mechanical stirring), a.u.	intensity of ibuprofen-Fe <sub>3</sub> O <sub>4</sub> -GO (ultrasound), a.u.
H <sup>+</sup>	61,240	57,102	60,375
CHO <sub>2</sub> <sup>+</sup>	11,707	478	1732
OH <sup>+</sup>	816	144	521
CO <sup>+</sup>	2148	633	1795
C <sub>2</sub> <sup>+</sup>	421	549	2007
FeO <sup>+</sup>		214	271
CFe <sup>+</sup>		197	843
COFe <sup>+</sup>		180	672
H <sup>+</sup>		57,102	60,375

concentration of H<sup>+</sup>, CHO<sub>2</sub><sup>+</sup>, OH<sup>+</sup>, and CO<sup>+</sup> than of complexed ibuprofen with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfrom. The excessive formation of cationic species on pristine ibuprofen can result from the second single-electron oxidation followed by the formation of a benzyl cation, acting as the substrate for the generation of final products: alcohol and ether. At the same time, the labile hydroperoxide can be also formed, which produces a mixture of alcohol and ketone as a result of the addition of oxygen to the benzyl radical.

The mass spectra reveal the concentration of C<sub>2</sub><sup>+</sup> ions being increased by ~4.8 in ultrasonically formed ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres in comparison with pristine ibuprofen, which can be caused by the increased number of complexed ibuprofen molecules in the use of ultrasound. Similarly, the concentration of C<sub>2</sub><sup>+</sup> ions of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO prepared under mechanical stirring was higher by ~3.7, indicating that complexation of ibuprofen molecules also takes place under mechanical agitation, but is less efficient than ultrasound. The intensity of detected ionic species such as FeO<sup>+</sup>, CFe<sup>+</sup>, and COFe<sup>+</sup> was also higher by ~1.3, ~4.3, and ~3.7 in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres being formed by ultrasound than under silent conditions, indicating the profound effect of sonochemical reactions on the complexation of ibuprofen with the Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfrom and iron-complexation.

However, the concentration of CHO<sub>2</sub><sup>+</sup>, OH<sup>+</sup>, and CO<sup>+</sup> is the highest in pristine ibuprofen and the lowest is in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres being formed under silent conditions. We can estimate that ~14.8% more CHO<sub>2</sub><sup>+</sup> ions are present in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres being formed with ultrasound than without it (~4.1%) in comparison with free ibuprofen per se. In a similar comparison, the amounts of more OH<sup>+</sup> ions are ~17.7% (silent) and ~63.9% (ultrasound), and more CO<sup>+</sup> are ~29.5% (silent) and ~83.6% (ultrasound) in ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres than in free ibuprofen per se, demonstrating the important role of CO bonds, COOH and OH groups in the complexation of ibuprofen with Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfrom, which is enhanced by ultrasound.

The ameliorated concentration of FeO<sup>+</sup>, CFe<sup>+</sup>, and COFe<sup>+</sup> on the surface of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres confirms our suggestions derived from the UV-vis absorbance results that ibuprofen forms complexes with mixed charge transfer and increased ligand field transitions of protonated Fe(II) complexes of this drug molecules in the close proximity of N and phenyl rings. In addition, these findings also support the data of CV measurements, which point out to the enhanced

'OH radical scavenging ability of ultrasonically formed ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO in contrast to pristine ibuprofen due to increased concentration of inactive protonated Fe(II) centers in Fe-O, C-Fe and CO-Fe bonds (FeO<sup>+</sup>, CFe<sup>+</sup> and COFe<sup>+</sup>) of complexed drug molecules and increased concentration of CHO<sub>2</sub><sup>+</sup>, OH<sup>+</sup> and CO<sup>+</sup> ions.

The increased concentration of inactive protonated Fe(II) centers could limit the accessibility of H<sub>2</sub>O<sub>2</sub> to the iron, which is related to the number of ligation sites occupied by the chelator. The increased number of protonated ionic species including H<sup>+</sup> on the surface of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres can alter the electro-Fenton mechanism so that little 'OH radicals are produced. In this way, the 'OH radical scavenging mechanism of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO is similar to the action of previously reported Fe<sub>3</sub>O<sub>4</sub>-rGO-SA NPs (salicylic acid complexed with rGO-Fe<sub>3</sub>O<sub>4</sub>) because both types of NPs act as redox deactivators of iron centers and increase H<sup>+</sup> generation, resulting in efficient diminishing of 'OH radicals. However, in contrast to SA-rGO-Fe<sub>3</sub>O<sub>4</sub>, ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres do not require addition of ascorbic acid and still exhibit antioxidant efficiency that is ~23.5 times higher than that of pristine ibuprofen and ~161.2 times higher activity than ibuprofen NPs.

#### 4. CONCLUSIONS

We have developed a feasible ultrasonic method (20 kHz) for in situ complexation of pristine ibuprofen molecules at the contact with preformed Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfrom by applying the "solvent:antisolvent" (ethanol:aqueous fluids) acoustic emulsification mechanism. As a result, ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres with a core-shell structure and an average size of ~51 nm were prepared. The ultrasonic complexation of pristine ibuprofen with the Fe<sub>3</sub>O<sub>4</sub>-GO nanoplatfrom occurs via the H-bond formation with the drug side chains (CH, CH<sub>2</sub> and CH<sub>3</sub>) and C-O-H interaction of carboxylic groups with Fe-O bonds.

Ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres are efficient 'OH scavengers in the electro-Fenton process with ~23.5 times higher diminishing rate efficiency than pristine ibuprofen and ~161.2 times higher activity than ibuprofen NPs. This pronounced antioxidant efficiency of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO is due to the increased concentration of inactive protonated Fe(II) centers in Fe-O, C-Fe, and CO-Fe bonds (FeO<sup>+</sup>, CFe<sup>+</sup>, and COFe<sup>+</sup>) of complexed drug molecules and increased concentration of CHO<sub>2</sub><sup>+</sup>, OH<sup>+</sup>, and CO<sup>+</sup> ions on the surface of nanospheres. As a result, ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO can limit the accessibility of H<sub>2</sub>O<sub>2</sub> to the iron and deactivate it and substantially decrease the production of 'OH radicals. This effect is enhanced via the neutralization of 'OH radicals with various cationic active species present on the surface of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres.

This new knowledge substantially improves the understanding of iron inactivation and free radical scavenging activity as two basic mechanisms of the ibuprofen antioxidant function that can be modulated by Fe<sub>3</sub>O<sub>4</sub>-GO at the nanoscale. The demonstrated method discloses the conditions of modulation and enhanced antioxidant efficiency of ibuprofen and can be potentially applied to other drugs.



## 908 ■ ASSOCIATED CONTENT

## 909 ■ Supporting Information

910 The Supporting Information is available free of charge at  
911 <https://pubs.acs.org/doi/10.1021/acsanm.3c05399>.

912 EDX spectra and SEM images of GO after first and  
913 second oxidation protocols; SEM image and EDX  
914 spectrum of the synthesized Fe<sub>3</sub>O<sub>4</sub>-GO nanoplateform;  
915 TEM images of ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO and pristine  
916 ibuprofen nanoparticles; Raman spectrum of bulk  
917 magnetite material; analysis of experimental FTIR  
918 transmittance spectra of pristine ibuprofen, GO,  
919 Fe<sub>3</sub>O<sub>4</sub>-GO nanoplateform, and ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO  
920 nanospheres; analysis of experimental XRD powder  
921 diffractograms of free ibuprofen per se; optical phase  
922 contrast microscopy images of pristine ibuprofen  
923 nanoparticles after 24 h of aging in a mother solution;  
924 and TOF SIMS mass spectra of free ibuprofen per se  
925 and ibuprofen-Fe<sub>3</sub>O<sub>4</sub>-GO nanospheres formed by  
926 mechanical stirring or ultrasound (PDF)

## 927 ■ AUTHOR INFORMATION

## 928 Corresponding Author

929 Darya Radziuk – Laboratory of Integrated Micro- and  
930 Nanosystems, Belarusian State University of Informatics and  
931 Radioelectronics, 220013 Minsk, Republic of Belarus;  
932 [orcid.org/0000-0003-1409-5357](https://orcid.org/0000-0003-1409-5357); Email: [radziuk@](mailto:radziuk@bsuir.by)  
933 [bsuir.by](mailto:bsuir.by)

## 934 Authors

935 Aleksey Drinevskiy – Laboratory of Integrated Micro- and  
936 Nanosystems, Belarusian State University of Informatics and  
937 Radioelectronics, 220013 Minsk, Republic of Belarus  
938 Evgenij Zelkovskiy – Laboratory of Integrated Micro- and  
939 Nanosystems, Belarusian State University of Informatics and  
940 Radioelectronics, 220013 Minsk, Republic of Belarus  
941 Vladimir Labunov – Laboratory of Integrated Micro- and  
942 Nanosystems, Belarusian State University of Informatics and  
943 Radioelectronics, 220013 Minsk, Republic of Belarus

944 Complete contact information is available at:

945 <https://pubs.acs.org/doi/10.1021/acsanm.3c05399>

## 946 Author Contributions

947 The manuscript was written through contributions of all  
948 authors. All authors have given approval to the final version of  
949 the manuscript.

## 950 Funding

951 This work was supported by the Belarusian Republican  
952 Foundation for Fundamental Research grant SCIENTIST  
953 No. F22Y-007 and Belarusian Ministry of Education Research  
954 grant No. 21-3067 1.17.

## 955 Notes

956 The authors declare no competing financial interest.

## 957 ■ ACKNOWLEDGMENTS

958 We acknowledge D. Zhigulin (Scientific-Technical Center  
959 “Belmicrosystems”, Minsk) for the analysis and helpful  
960 discussion in the use of time-of-flight secondary-ion mass  
961 spectrometry, Dr. K.V. Skrotskaya for insightful TEM analysis  
962 (Belarusian State University), Prof. V.P. Bondarenko for access  
963 to Metrohm Autolab potentiostat/galvanostat instrument, and  
964 T. Rysalskaya for assistance in the synthesis of graphene oxide

(Belarusian State University of Informatics and Radioelec- 965  
tronics). 966

## 967 ■ REFERENCES

- (1) Mazaleuskaya, L. L.; Theken, K. N.; Gong, L.; Thorn, C. F.; 968  
FitzGerald, G. A.; Altman, R. B.; Klein, T. E. PharmGKB summary: 969  
ibuprofen pathways. *Pharmacogenet Genomics* **2015**, *25*, 96–106. 970
- (2) Petrat, F.; de Groot, H.; Sustmann, R.; Rauen, U. The chelatable 971  
iron pool in living cells: a methodically defined quantity. *Biol. Chem.* 972  
**2002**, *383*, 489–502. 973
- (3) Kehrer, J. P. The Haber-Weiss reaction and mechanisms of 974  
toxicity. *Toxicology* **2000**, *149*, 43–50. 975
- (4) Poprac, P.; Jomova, K.; Simunkova, M.; Kollar, V.; Rhodes, C. J.; 976  
Valko, M. Targeting free radicals in oxidative stress-related human 977  
diseases. *Trends Pharmacol. Sci.* **2017**, *38*, 592–607. 978
- (5) Naruszewicz, M.; Zapolski-Downar, A.; Markiewski, M.; 979  
Bukowska, H.; Millo, B. Ibuprofen inhibits adhesiveness of monocytes 980  
to endothelium and reduces cellular oxidative stress in smokers and 981  
non-smokers. *Eur. J. Clin. Invest.* **2000**, *30*, 1002–1010. 982
- (6) Zapolska-Downar, D.; Naruszewicz, M. A pleiotropic anti- 983  
atherogenic action of ibuprofen. *Med. Sci. Monit.* **2001**, *7*, 837–841. 984
- (7) Zapolska-Downar, D.; Zapolski-Downar, A.; Bukowska, H.; 985  
Galka, H.; Naruszewicz, M. Ibuprofen protects low density 986  
lipoproteins against oxidative modification. *Life Sci.* **1999**, *65*, 987  
2289–2303. 988
- (8) Cohen, G. The Fenton reaction. In *Handbook of Methods for* 989  
*Oxygen Radical Research*; Greenwald, R. A., Ed.; CRC Press, Inc.: 990  
Boca Raton, FL, 1985; pp 55–69. 991
- (9) Orhan, H.; Şahin, G. In vitro effects of NSAIDs and paracetamol 992  
on oxidative stress-related parameters of human erythrocytes. *Exp.* 993  
*Toxic Pathol.* **2001**, *53*, 133–140. 994
- (10) Hamburger, S. A.; McCay, P. B. Spin trapping of ibuprofen 995  
radicals: evidence that ibuprofen is a hydroxyl radical scavenger. *Free* 996  
*Rad. Reg. Comms.* **1990**, *9*, 337–342. 997
- (11) Van Antwerpen, P.; Nève, J. In vitro comparative assessment of 998  
the scavenging activity against three reactive oxygen species of non- 999  
steroidal anti-inflammatory drugs from the oxamic and sulfoanilide 1000  
families. *Eur. J. Pharmacol.* **2004**, *496*, 55–61. 1001
- (12) Kennedy, T. P.; Rao, N. V.; Noah, W.; Michael, J. R.; Jafri, M. 1002  
H.; Gurtner, G. H.; Hoidal, J. R. Ibuprofen prevents oxidant lung 1003  
injury and in vitro lipid peroxidation by chelating iron. *J. Clin. Invest.* 1004  
**1990**, *86*, 1565–1573. 1005
- (13) Albert, A. Chemical aspects of selective toxicity. *Nature* **1958**, 1006  
*182* (4633), 421–422. 1007
- (14) Banti, C. N.; Hadjikakou, S. K. Non-steroidal anti-inflammatory 1008  
drugs (NSAIDs) in metal complexes and their effect at the cellular 1009  
level. *Eur JIC* **2016**, *2016*, 3048–3071. 1010
- (15) Liu, Q.; Du, K.; Liu, M.; Lv, R.; Sun, B.; Cao, D.; He, N.; 1011  
Wang, Z. Sulfosalicylic acid/Fe<sup>3+</sup> based nanoscale coordination 1012  
polymers for effective cancer therapy by the Fenton reaction: an 1013  
inspiration for understanding the role of aspirin in the prevention of 1014  
cancer. *Biomater. Sci.* **2019**, *7*, 5482–5491. 1015
- (16) Kataoka, M. A.; Tonooka, K.; Ando, T.; Imai, K.; Aimoto, T. 1016  
Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory 1017  
drugs. *Free Radic. Res.* **1997**, *27*, 419–427. 1018
- (17) Mikhnayets, L.; Abashkin, V.; Khamitsevich, H.; Shcharbin, D.; 1019  
Burko, A.; Krekoten, N.; Radziuk, D. Ultrasonic formation of Fe<sub>3</sub>O<sub>4</sub> 1020  
reduced graphene oxide-salicylic acid nanoparticles with switchable 1021  
antioxidant function. *ACS Biomater. Sci. Eng.* **2022**, *8*, 1181–1192. 1022
- (18) Alegret, N.; Criado, A.; Prato, M. Recent advances of graphene- 1023  
based hybrids with magnetic nanoparticles for biomedical applica- 1024  
tions. *Curr. Med. Chem.* **2017**, *24*, 529–536. 1025
- (19) Zhang, Y.; Zhang, Y.; Yang, Z.; Fan, Y.; Chen, M.; Zhao, M.; 1026  
Dai, B.; Zheng, L.; Zhang, D. Cytotoxicity effect of iron oxide 1027  
(Fe<sub>3</sub>O<sub>4</sub>)/graphene oxide (GO) nanosheets in cultured HBE cells. 1028  
*Front Chem.* **2022**, *10*, No. 888033. 1029
- (20) Wang, Q.; Zhang, X.; Huang, L.; Zhang, Z.; Dong, S. One-pot 1030  
synthesis of Fe<sub>3</sub>O<sub>4</sub> nanoparticle-loaded 3D porous graphene nano- 1031

- 1032 composites with enhanced nanozyme activity for glucose detection. 1101  
1033 *ACS Appl. Mater. Interfaces* **2017**, *9*, 7465–7471. 1102
- 1034 (21) Yang, X.; Zhang, X.; Ma, Y.; Wang, Y.; Chen, Y. 1103  
1035 Superparamagnetic graphene oxide–Fe<sub>3</sub>O<sub>4</sub> nanoparticles hybrid for 1104  
1036 controlled targeted drug carriers. *J. Mater. Chem.* **2009**, *19*, 2710– 1105  
1037 2714. 1106
- 1038 (22) Wang, G.; Chen, G.; Wei, Z.; Dong, X.; Qi, M. Multifunctional 1107  
1039 Fe<sub>3</sub>O<sub>4</sub>/graphene oxide nanocomposites for magnetic resonance 1108  
1040 imaging and drug delivery. *Mater. Chem. Phys.* **2013**, *141*, 997–1004. 1109
- 1041 (23) Shen, J.-M.; Gao, F.-Y.; Guan, L.-P.; Su, W.; Yang, Y.-J.; Lia, Q.- 1110  
1042 R.; Jin, Z.-C. Graphene oxide–Fe<sub>3</sub>O<sub>4</sub> nanocomposite for combination 1111  
1043 of dual-drug chemotherapy with photothermal therapy. *RSC Adv.* 1112  
1044 **2014**, *4*, 18473–18484. 1113
- 1045 (24) Fiadosenka, U.; Matsukovich, A.; Tabulina, L.; Labunov, V.; 1114  
1046 Radziuk, D. The properties of the sonochemically functionalized 1115  
1047 nonsteroidal anti-inflammatory drug ketorolac in Fe<sub>3</sub>O<sub>4</sub>-graphene 1116  
1048 oxide nanocomposite. *New J. Chem.* **2019**, *41*, 16118–16122. 1117
- 1049 (25) Tkach, A.; Fiadosenka, U.; Burko, A.; Bandarenka, H. V.; 1118  
1050 Matsukovich, A.; Krekoten, N.; Tabulina, L.; Labunov, V.; Radziuk, 1119  
1051 D. Polyvinyl alcohol enhances acetylation of ascorbic acid in 1120  
1052 superparamagnetic-graphene oxide nanoparticles ultrasonically com- 1121  
1053 plexed with acetylsalicylic acid. *ACS Appl. Polym. Mater.* **2020**, *2*, 1122  
1054 3663–3673. 1123
- 1055 (26) Nel, J.; Siniscalco, D.; Hognon, C.; Bouché, M.; Touche, N.; 1124  
1056 Brunner, E.; Gros, P. C.; Monari, A.; Grandemange, S.; Francius, G. 1125  
1057 Structural and morphological changes of breast cancer cells induced 1126  
1058 by iron(II) complexes. *Nanoscale* **2022**, *14*, 2735–2749. 1127
- 1059 (27) Meier-Menches, S. M.; Casini, A. Design strategies and 1128  
1060 medicinal applications of metal-peptidic bioconjugates. *Bioconjugate* 1129  
1061 *Chem.* **2020**, *31*, 1279–1288. 1130
- 1062 (28) Zegers, J.; Peters, M.; Albada, B. DNA G-quadruplex-stabilizing 1131  
1063 metal complexes as anticancer drugs. *JBC* **2023**, *28*, 117–138. 1132
- 1064 (29) Xue, X.; Qian, C.; Tao, Q.; Dai, Y.; Lv, M.; Dong, J.; Su, Z.; 1133  
1065 Qian, Y.; Zhao, J.; Liu, H.-K.; Guo, Z. Using bio-orthogonally 1134  
1066 catalyzed lethality strategy to generate mitochondria-targeting anti- 1135  
1067 tumor metallodrugs in vitro and in vivo. *Natl. Sci. Rev.* **2021**, *8*, 1136  
1068 No. nwa286, DOI: 10.1093/nsr/nwa286. 1137
- 1069 (30) Wang, H.; Zhou, Y.; Xu, X.; Li, H.; Sun, H. Metalloproteomics 1138  
1070 in conjunction with other omics for uncovering the mechanism of 1139  
1071 action of metallodrugs: mechanism-driven new therapy development. 1140  
1072 *Curr. Opin. Chem. Biol.* **2020**, *55*, 171–179. 1141
- 1073 (31) Radziuk, D.; Mikhnayets, L.; Vorokhta, M.; Matolín, V.; 1142  
1074 Tabulina, L.; Labunov, V. Sonochemical formation of copper/iron- 1143  
1075 modified graphene oxide nanocomposites for ketorolac delivery. 1144  
1076 *Chem. – Eur. J.* **2019**, *25*, 6233–6245. 1145
- 1077 (32) Suslick, K. S. The dawn of ultrasonics and the palace of science. 1146  
1078 *Acoust. Today* **2019**, *15*, 38–46. 1147
- 1079 (33) Suslick, K. S. *Sonochemistry*. *Science* **1990**, *247*, 1439–1445. 1148
- 1080 (34) Weissler, A. Formation of hydrogen peroxide by ultrasonic 1149  
1081 waves: free radicals. *J. Am. Chem. Soc.* **1959**, *81*, 1077–1081. 1150
- 1082 (35) Shimanovich, U.; Gedanken, A. Nanotechnology solutions to 1151  
1083 restore antibiotic activity. *J. Mater. Chem. B* **2016**, *4*, 824–833. 1152
- 1084 (36) Zeiger, B. W.; Suslick, K. S. Sonofragmentation of molecular 1153  
1085 crystals. *J. Am. Chem. Soc.* **2011**, *133*, 14530–14533. 1154
- 1086 (37) Kim, H. N.; Suslick, K. S. Sonofragmentation of organic 1155  
1087 molecular crystals vs strength of materials. *J. Org. Chem.* **2021**, *86*, 1156  
1088 13997–14003. 1157
- 1089 (38) Grinberg, O.; Shimanovich, U.; Gedanken, A. Encapsulating 1158  
1090 bioactive materials in sonochemically produced micro-and nano- 1159  
1091 spheres. *J. Mater. Chem. B* **2013**, *1*, 595–605. 1160
- 1092 (39) Mukh-Qasem, R. A.; Gedanken, A. Sonochemical synthesis of 1161  
1093 stable hydrosol of Fe<sub>3</sub>O<sub>4</sub> nanoparticles. *J. Colloid Interface Sci.* **2005**, 1162  
1094 *284*, 489–494. 1163
- 1095 (40) Zhu, S.; Guo, J.; Dong, J.; Cui, Z.; Lu, T.; Zhu, C.; Zhang, D.; 1164  
1096 Mac, J. Sonochemical fabrication of Fe<sub>3</sub>O<sub>4</sub> nanoparticles on reduced 1165  
1097 graphene oxide for biosensors. *Ultrason. Sonochem.* **2013**, *20*, 872– 1166  
1098 880. 1167
- 1099 (41) Niu, G.; Yousefi, B.; Qujeq, D.; Marjani, A.; Asadi, J.; Wang, Z.; 1168  
1100 Mir, S. M. Melatonin and doxorubicin co-delivered via a function- 1169  
1101 enhanced graphene-dendrimeric system enhances apoptosis of osteosar- 1170  
1102 coma cells. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2021**, *119*, 1171  
1103 No. 111554. 1172
- (42) Wang, Z.; Zhou, C.; Xia, J.; Via, B.; Xia, Y.; Zhang, F.; Li, Y.; 1173  
1104 Xia, L. Fabrication and characterization of a triple functionalization of 1174  
1105 graphene oxide with Fe<sub>3</sub>O<sub>4</sub>, folic acid and doxorubicin as dual- 1175  
1106 targeted drug nanocarrier. *Colloids Surf. B: Biointerfaces* **2013**, *106*, 1176  
1107 60–65. 1177
- (43) Li, N.; Chen, J.; Shi, Y.-P. Magnetic polyethyleneimine 1178  
1109 functionalized reduced graphene oxide as a novel magnetic sorbent 1179  
1110 for the separation of polar non-steroidal anti-inflammatory drugs in 1180  
1111 waters. *Talanta* **2019**, *191*, 526–534. 1181
- (44) Li, G.; Deng, R.; Peng, G.; Yang, C.; He, Q.; Lu, Y.; Shi, H. 1182  
1113 Magnetic solid-phase extraction for the analysis of bisphenol A, 1183  
1114 naproxen and triclosan in wastewater samples. *Water Sci. Technol.* 1184  
1115 **2018**, *77*, 2220–2227. 1185
- (45) Yuvali, D.; Narin, I.; Soylak, M.; Yilmaz, E. Green synthesis of 1186  
1117 magnetic carbon nanodot/graphene oxide hybrid material (Fe<sub>3</sub>O<sub>4</sub>@ 1187  
1118 C-nanodot@GO) for magnetic solid phase extraction of ibuprofen in 1188  
1119 human blood samples prior to HPLC-DAD determination. *J. Pharm.* 1189  
1120 *Biomed. Anal.* **2020**, *179*, No. 113001. 1190
- (46) Cao, L.; Jiang, Y.; Chen, Z. Hollow Fe<sub>3</sub>O<sub>4</sub>/graphene oxide 1191  
1122 nanocomposites as novel rapamycin carrier: formulation optimization 1192  
1123 and in vitro characterization. *J. Nanosci. Nanotechnol.* **2018**, *18*, 3067– 1193  
1124 3076. 1194
- (47) Asgharinezhad, A. A.; Ebrahimzadeh, H. Poly(2-amino- 1195  
1126 benzothiazole)-coated graphene oxide/magnetite nanoparticles com- 1196  
1127 posite as an efficient sorbent for determination of non-steroidal anti- 1197  
1128 inflammatory drugs in urine sample. *J. Chromatogr. A* **2016**, *1435*, 1198  
1129 18–29. 1199
- (48) Jacintho, G. V. M.; Brolo, A. G.; Corio, P.; Suarez, P. A. Z.; 1200  
1131 Rubim, J. C. Structural investigation of MFe<sub>2</sub>O<sub>4</sub> (M = Fe, Co) 1201  
1132 magnetic fluids. *J. Phys. Chem. C* **2009**, *113*, 7684–7691. 1202
- (49) Knight, D. S.; White, W. B. Characterization of diamond films 1203  
1134 by Raman spectroscopy. *J. Mater. Res.* **1989**, *4*, 385–393. 1204
- (50) Ferrari, A. C.; Robertson, J. Interpretation of Raman spectra of 1205  
1136 disordered and amorphous carbon. *Phys. Rev. B* **2000**, *61*, 14095– 1206  
1137 14107. 1207
- (51) Jubert, A.; Legarto, M. L.; Massa, N. E.; Tévez, L. L.; Okulik, N. 1208  
1139 B. Vibrational and theoretical studies of non-steroidal anti- 1209  
1140 inflammatory drugs Ibuprofen [2-(4-isobutylphenyl)propionic acid]; 1210  
1141 Naproxen [6-methoxy- $\alpha$ -methyl-2-naphthalene acetic acid] and 1211  
1142 Tolmetin acids [1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic 1212  
1143 acid]. *J. Mol. Struct.* **2006**, *783*, 34–51. 1213
- (52) Gera, T.; Nagy, E.; Smausz, T.; Budai, J.; Ajtai, T.; Kun-Szabó, 1214  
1144 F.; Homik, Z.; Kopniczky, J.; Bozóki, Z.; Szabó-Révész, P.; Ambrus, 1215  
1145 R.; Hopp, B. Application of pulsed laser ablation (PLA) for the size 1216  
1146 reduction of non-steroidal anti-inflammatory drugs (NSAIDs). *Sci.* 1217  
1147 *Rep.* **2020**, *10*, 15806. 1218
- (53) Soler, M. A. G.; Qu, F. Raman spectroscopy of iron oxide 1219  
1148 nanoparticles. In Challa S. S. R., Kumar, Ed.; *Raman Spectroscopy for* 1220  
1149 *Nanomaterials Characterization*; Springer-Verlag: Berlin Heidelberg, 1221  
1150 2012; p 404. 1222
- (54) Solbrig, R. M.; Duff, L. L.; Shriver, D. F.; Klotz, I. M. Raman 1223  
1151 and infrared spectroscopy of the oxo-bridged iron(III) complex, 1224  
1152 [Cl<sub>3</sub>Fe-O-FeCl<sub>3</sub>]<sup>-2</sup> as a spectroscopic model for the oxo bridge in 1225  
1153 hemerythrin and ribonucleotide reductase. *J. Inorg. Biochem.* **1982**, *17*, 1226  
1154 69–74. 1227
- (55) Verble, J. L. Temperature-dependent light-scattering studies of 1228  
1155 the Verwey transition and electronic disorder in magnetite. *Phys. Rev.* 1229  
1156 *B* **1974**, *9*, 5236. 1230
- (56) Chamritski, I.; Burns, G. Infrared- and Raman-active phonons 1231  
1157 of magnetite, maghemite, and hematite, a computer simulation and 1232  
1158 spectroscopic study. *J. Phys. Chem. B* **2005**, *109*, 4965–4968. 1233
- (57) Sehested, K.; Corfitzen, H.; Christensen, H. C.; Hart, E. J. 1234  
1159 Rates of reaction of oxygen(1-) ions, hydroxyl radicals, and atomic 1235  
1160 hydrogen with methylated benzenes in aqueous solution. Optical 1236  
1161 spectra of radicals. *J. Phys. Chem.* **1975**, *79*, 310–315. 1237

- 1169 (58) Musa, K. A. K.; Eriksson, L. A. Theoretical study of ibuprofen  
1170 phototoxicity. *J. Phys. Chem. B* **2007**, *111*, 13345–13352.
- 1171 (59) Illés, E.; Takács, E.; Dombi, A.; Gajda-Schranz, K.; Rácz, G.;  
1172 Gonter, K.; Wojnárovits, L. Hydroxyl radical induced degradation of  
1173 ibuprofen. *Sci. Total Environ.* **2013**, *447*, 286–292.
- 1174 (60) Jasim, D. A.; Lozano, N.; Kostarelos, K. Synthesis of few-  
1175 layered, high-purity graphene oxide sheets from different graphite  
1176 sources for biology. *2D Mater.* **2016**, *3*, No. 014006.
- 1177 (61) Mürbe, J.; Rechtenbach, A.; Töpfer, J. Synthesis and physical  
1178 characterization of magnetite nanoparticles for biomedical application.  
1179 *Mater. Chem. Phys.* **2008**, *110*, 426–433.
- 1180 (62) Dimiev, A. M.; Alemany, L. B.; Tour, J. M. Graphene oxide.  
1181 Origin of acidity, its instability in water, and a new dynamic structural  
1182 model. *ACS Nano* **2013**, *7*, 576–658.
- 1183 (63) Dimiev, A. M.; Ceriotti, G.; Behabtu, N.; Zakhidov, D.;  
1184 Pasquali, M.; Saito, R.; Tour, J. M. Direct real - time monitoring of  
1185 stage transitions in graphite intercalation compounds. *ACS Nano*  
1186 **2013**, *7*, 2773–2780.
- 1187 (64) Rozel, P.; Radziuk, D.; Mikhnavev, L.; Khokhlov, E.; Shiripov,  
1188 V.; Matolínová, I.; Matolín, V.; Basaev, A.; Kargin, N.; Labunov, V.  
1189 Properties of nitrogen/silicon doped vertically oriented graphene  
1190 produced by ICP CVD roll-to-roll technology. *Coatings* **2019**, *9*, 60.
- 1191 (65) Chen, S.; Xi, H.; Henry, R. F.; Marsden, L.; Zhang, G. G. Z.  
1192 Chiral co-crystal solid solution: structures, melting point phase  
1193 diagram, and chiral enrichment of (ibuprofen)<sub>2</sub>(4,4-dipyridyl).  
1194 *CrystEngComm* **2010**, *12*, 1485–1493.
- 1195 (66) Rossi, P.; Macedi, E.; Paoli, P.; Bernazzani, L.; Carignani, E.;  
1196 Borsacchi, S.; Geppi, M. Solid-solid transition between hydrated  
1197 racemic compound and anhydrous conglomerate in Na-ibuprofen: A  
1198 combined X-ray diffraction. Solid-state NMR, Calorimetric, and  
1199 computational study. *Cryst. Growth Des.* **2014**, *14*, 2441–2452.
- 1200 (67) Nakagiri, N.; Manghnani, M. H.; Ming, L. C.; Kimura, S.  
1201 Crystal structure of magnetite under pressure. *Phys. Chem. Miner.*  
1202 **1986**, *13*, 238–244.
- 1203 (68) Gatta, G. D.; Kantor, I.; Ballaran, T. B.; Dubrovinsky, L.;  
1204 McCammon, C. Effect of non-hydrostatic conditions on the elastic  
1205 behaviour of magnetite: an in situ single-crystal X-ray diffraction  
1206 study. *Phys. Chem. Miner.* **2007**, *34*, 627–635.
- 1207 (69) Ostrowska, K.; Kropidłowska, M.; Katrusiak, A. High-pressure  
1208 crystallization and structural transformations in compressed R. S-  
1209 *ibuprofen*. *Cryst. Growth Des.* **2015**, *15*, 1512–1517.
- 1210 (70) Lima, A. B.; Faria, E. O.; Montes, R. H. O.; Cunha, R. R.;  
1211 Richter, E. M.; Munoz, R. A. A.; dos Santos, W. T. P. Electrochemical  
1212 oxidation of ibuprofen and its voltammetric determination at a boron-  
1213 doped diamond electrode. *Electroanalysis* **2013**, *25*, 1585–1588.